Alpa Laboratories Ltd has accepted the resignation of Ms. Yashoda Patidar from the position of Company Secretary and Compliance Officer. The resignation is effective from the close of business hours on July 26, 2026, due to personal reasons. The company informed the National Stock Exchange of India Limited and Bombay Stock Exchange Limited regarding this change in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015.

Ms. Yashoda Patidar submitted her resignation letter dated July 08, 2026, to Mr. Mahendra Singh Chawla, Director of Alpa Laboratories Limited. In her communication, she stated that she would ensure a smooth transition of responsibilities during the notice period and complete all pending assignments to maintain continuity of work.

The disclosure was made by Mahendra Singh Chawla, Director, on behalf of Alpa Laboratories Limited. The company has provided the necessary details regarding the cessation of the officer in Annexure A of the regulatory filing.

Details of Resignation

Alpa Laboratories reported a 24% decline in consolidated net profit for the financial year ended March 31, 2026, to ₹15.01 crore, down from ₹19.50 crore in the previous year. Revenue from operations for the period decreased to ₹105.81 crore compared to ₹112.45 crore in FY25. The standalone net profit for FY26 stood at ₹14.95 crore, a decrease from ₹19.68 crore in the prior year, with revenue from operations at ₹105.81 crore versus ₹111.64 crore.

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹1.38 crore, a turnaround from the net loss of ₹2.12 crore recorded in the same period last year. Revenue from operations for the quarter stood at ₹31.40 crore. Standalone net profit for the quarter was ₹1.36 crore, compared to a net loss of ₹1.95 crore in the corresponding quarter of the previous year.

The Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, at a meeting held on May 29, 2026. Statutory auditors M/s C.H Padliya & Co. issued an audit report with an unmodified opinion on the financial results. The company operates in a single segment, Drugs & Chemicals.

The board appointed M/s S. S. Gandhi & Associates as the Internal Auditor and M/s. Sudeep Saxena & Associates as the Cost Auditor for the financial year 2026-27. The meeting commenced at 4:00 PM and concluded at 10:00 PM on May 29, 2026.

Financial Performance Summary